BIOMARKERS
SERIES UK 2020

18 - 20 February 2020 | Manchester Central, Manchester, UK

15th Annual Biomarkers Congress
+ Co-located Genomic Markers Congress

450+ LEADING BIOTECH, PHARMA AND ACADEMIC DELEGATES
70+ PRESENTATIONS, CASE STUDIES AND DISCUSSIONS
4+ PRE-EVENT DEEP DIVE SESSIONS & WORKSHOPS

Conference Brochure

KEY SPEAKERS INCLUDE

Holly Soares
Pfizer
Katherine Call
Sanofi
Mark Fidock
AstraZeneca
Marianne Scheel Fjording
Novo Nordisk
Ziad Taib
AstraZeneca
Thomas Misko
AbbVie

Book Online: www.oxfordglobal.co.uk/biomarkers-series-uk/
Join the Conversation: #BIOMUK20
Oxford Global is proud to present for the 15th year our flagship Biomarkers Series, featuring over 70 speakers and 45 leading solution provider companies to ensure you gain vital updates on novel biomarker initiatives and technologies impacting the community. It unites over 450 senior-level attendees to provide a focused forum for thought-provoking discussion.

Biomarkers remain fundamental to all stages of drug development. Reflecting this, the congress provides a comprehensive look at the current trends, technologies and data impacting biomarker research across the development pipeline – from early discovery through to the clinic. Case studies within all sessions focus on market-dominating therapeutic areas including oncology and neuroscience, alongside key fast-emerging areas such as cardiovascular disorders and immunology.

To enhance the interactivity of the programme and maximise your networking opportunities, we have also incorporated an increased amount of discussion opportunities in the conference programme. Join us on Day 1 for the latest data in our popular workshop on Biomarker Qualification: Technical Validation and Regulatory Aspects. Day 2 is kick-started by our roundtable discussions on a variety of key themes within this industry, whilst we also feature two workshops later in the day on Integrated Different Biomarker Data for Successful Drug and Diagnostic Development and Genomic Biobanking to Facilitate Precision Medicine.

New for 2020, the event has been extended to include a pre-event focus day featuring deep-dive therapeutic sessions, allowing for an in-depth look at the latest biomarker data and strategies impacting oncology, neuroscience and cardiology. Spaces at the sessions are limited, so do sign up early to avoid disappointment.

We are also pleased to announce the launch of our Genomic Markers Congress as part of the series, providing you with actionable insights into the best strategies to integrate these technologies into the biomarker workflow and enable precision medicine.

With 2020 bringing a host of new features alongside our popular event features, it promises to be our best and biggest Biomarker Series yet. We look forward to welcoming you there!

- Jessica Thomson, Senior Conference Producer
WHO IS ATTENDING?

450+ VPs, Directors & Senior Managers from leading life sciences companies and research institutions in the following fields:

- Biomarker Discovery
- Translational Science
- Clinical Development
- Assay Development
- Genomic Markers
- Diagnostics
- Personalised Medicine
- Preclinical Safety & Efficacy
- Biomarker Validation
- Oncology Biomarkers
- Neuroscience
- Translational Medicine

These companies and many more

For the full attendee list please contact marketing@oxfordglobal.co.uk

WHO IS SPONSORING?

- Biomarker Discovery
- Genomic Markers
- Biomarker Validation
- Translational Science
- Diagnostics
- Personalised Medicine
- Preclinical Safety & Efficacy
- Oncology Biomarkers
- Neuroscience
- Translational Medicine

Formal and informal meeting opportunities offer delegates the chance to meet with leading service providers and discuss key solutions including:

- Assay Kits & Platforms
- Biomarker Verification
- Companion Diagnostics
- Protein Biomarkers
- Clinical Research & Trial Development
- Genomic Technologies
- Imaging Tools
- Liquid Biopsy
- Plexing Platforms
- Immunoassays
- Data Management
- Biomarker Discovery & Development

NETWORK AND PROGRAMME
Presentations will discuss:
- Updates in predictive biomarkers for drug development
- Check point inhibitors and dual therapies in immuno-oncology
- Biomarker discovery in oncology and autoimmunity
- Translational biomarkers and patient stratification

PLUS Workshop: Biomarker Qualification: Technical Validation And Regulatory Aspects
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Welcome Address</td>
<td>Facilitator: ANKA EHRRHARDT, Science Director, CHDI Foundation</td>
</tr>
</tbody>
</table>
| 10:10    | Sample Collection And Datasets For Finding And Making Biomarkers Available For Neurodegenerative Conditions | • Huntington's disease as genetically defined disease and the search for biomarkers  
  • Sample collection through platform studies  
  • Purposing samples for the disease research community  
  • Focused sample analysis results to support the search for treatments  
  ANKA EHRRHARDT, Science Director, CHDI Foundation |
| 10:40    | Striatal Astrocytes And Huntington's Disease | • Astrocyte dysfunction in Huntington's disease  
  • Astrocyte mutant-HTT cell autonomous effects  
  BLANCA DÍAZ CASTRO, UK DRI Programme Leader (Fellow), University of Edinburgh |
| 10:00    | Welcome Address                              | Facilitator: PIA DAVIDSSON, Head of Biomarkers, Discovery and Development, Translational Science and Experimental Medicine, AstraZeneca |
| 10:10    | Facing Challenges With New Cardiovascular Biomarkers | • Biomarkers as a mean of successful drug development  
  • The usefulness of biomarkers at each step of drug development: from target engagement to therapeutic response  
  • Challenges associated with the novel CV drug targets and phase II to III transition  
  • Opportunities: examples of novel tools and methods  
  BENOIT TYL, Director of Cardiovascular Translational and Clinical Research, Servier |
| 10:40    | Molecular Subtyping In Colorectal Cancer To Enable Improved Clinical Stratification | • Overview of molecular subtyping approaches currently used in colorectal cancer (CRC) research  
  • Limitations that potentially restrict clinical implementation  
  • Combining subtyping and histological assessment using clinical samples  
  PHILIP DUNNE, Lecturer, Centre for Cancer Research and Cell Biology, Queen's University Belfast |
| 11:10    | Transcriptome-Based Biomarkers In Breast Cancer | • Molecular heterogeneity of breast cancers  
  • Identification of genomic signatures to predict treatment response  
  • Lessons learnt from the development of genomic tests  
  MAGGIE CHEANG, Team Leader, The Institute of Cancer Research |
Title To Be Confirmed
Identification And Development Of Biomarkers For Assessment Of Target Engagement In Cardiovascular, Renal And Metabolism Diseases
• Our focus is to make effective decisions by using biomarkers, from pre-clinical research through all clinical phases. When each drug discovery project enters the portfolio, a dedicated biomarker strategy is therefore developed, with the aim to generate relationship between exposure, biomarkers for TE and PoM, and to disease biomarkers
• The key steps in the biomarker journey from biomarker identification to clinical application will be described
• There is always a need to explore and implement new technologies for development of TE and PoM biomarkers. Examples will be presented:
  1. Metabolomics for identification of new biomarkers and pathways in heart failure
  2. Pros / cons for ex vivo biomarkers vs. endogenous biomarkers as decision making biomarkers
  3. CETSA as target engagement assay for intracellular targets
  4. Development of biomarker panels based on LC MS technology
PIA DAVIDSSON, Head of Biomarkers, Discovery and Development, Translational Science and Experimental Medicine, AstraZeneca

Gene Expression And Spatial Biomarkers Using Machine Learning Approaches And Multiplex IHC In Gastrointestinal Cancers
• There is an urgent need to personalise therapy in colorectal cancer
• Machine learning approaches provide opportunities to integrate genomics data with therapy responses to identify potential predictive biomarkers
• We have used machine learning approaches in colon and rectal cancers to identify predictive gene biomarkers that represent both inter- and intra-tumoural heterogeneity and therapy responses (including immunotherapy and radiotherapy)
• Finally, we are currently applying machine learning approaches to identify spatial biomarkers of therapy responses
ANGURAJ SADANANDAM, Team Leader, Systems and Precision Cancer Medicine, The Institute of Cancer Research

Panel Discussion: Discovering Novel Biomarkers For Neurodegenerative Disease
Panellists:
ANKA EHRHARDT, Science Director, CHDI Foundation
BLANCA DÍAZ CASTRO, UK DRI Programme Leader (Fellow), University of Edinburgh

Panel Discussion: Novel Biomarkers For Cardiovascular And Inflammatory Conditions
Panellists:
PIA DAVIDSSON, Head of Biomarkers, Discovery and Development, Translational Science and Experimental Medicine, AstraZeneca
BENOIT TYL, Director of Cardiovascular Translational Research, Servier
JAMES R TURK, Pathology Director, Functional Area Lead, Translational Cardiovascular Pathology and Biomarkers, Safety Pharmacology and Animal Research Center, Translational Safety and Bianalytical Sciences, Amgen Research, Thousand Oaks, CA, USA

Panel Discussion: Multi-Modal Biomarkers For Cancer Detection And Treatment
Panellists:
PIA DAVIDSSON, Head of Biomarkers, Discovery and Development, Translational Science and Experimental Medicine, AstraZeneca
MAGGIE CHEANG, Team Leader, The Institute of Cancer Research
PHILIP DUNNE, Lecturer, Centre for Cancer Research and Cell Biology, Queen’s University Belfast

Closing Remarks
ANKA EHRHARDT, Science Director, CHDI Foundation
ANGURAJ SADANANDAM, Team Leader, Systems and Precision Cancer Medicine, The Institute of Cancer Research

Lunch
**Designing And Applying A Biomarker Plan In Drug Development**

Industry leaders in biomarkers and companion diagnostics, regulatory and technology come together to discuss challenges and effective biomarker strategies throughout the entire drug development continuum.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker To Be Announced</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Welcome, Introductions &amp; Overview</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td>The Role Of Biomarkers In Precision Medicine Along The Drug Development Continuum</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td>Innovations In Genomic Technology And Data Delivery</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>Regulatory Transition From Biomarker-Driven Drug Development And Outsourcing Considerations Moving To CDx</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Partnerships Driving Success - Roche &amp; Covance Neuroscience</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>CUE-101 Phase 1 Trial In HNSCC Patients: Novel Immunotherapy Enabled By Patient Stratification &amp; Pharmacodynamic Biomarkers</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Close Of Workshops &amp; End Of Pre-Event Focus Day</td>
<td></td>
</tr>
</tbody>
</table>
DAY ONE: 19 FEBRUARY 2020

07:30 - 08:20
Registration: Charter Foyer

15TH ANNUAL BIOMARKERS CONGRESS

Conference Room: Charter 4
Oxford Global Welcome Address

Chairperson's Opening Address: SUSO PLATERO, Global Leader Precision Medicine, Head Biomarker Solution Center, Covance

Keynote Address: Application Of Translational Biomarker Strategies To Streamline Clinical Development
- Application of proof of mechanism to inform dose selection
- Effective patient stratification and process to identify patient enrichment markers
- Enabling biomarker tools for differentiation

HOLLY SOARES, Head of Precision Medicine and Vice President, Pfizer

BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT – THERAPEUTIC AREAS:
Oncology & Immunology

Conference Room: Charter 4

Stream Chair: SUSO PLATERO, Global Leader Precision Medicine, Head Biomarker Solution Center, Covance

Biomarkers From Discovery To Commercialization: The Erdafitinib Story
- Exploring the role of biomarkers in early clinical development
- Understanding the benefits of incorporating a biomarker strategy into your clinical trial design
- Erdafitinib as a case study demonstrating faster progress from the use of biomarkers

SUSO PLATERO, Global Leader Precision Medicine, Head Biomarker Solution Center, Covance

Maximizing Immunotherapy Biomarker Discovery With An Advanced Tumor Immunogenomics Platform
- The complexity of the tumor and tumor microenvironment suggests a comprehensive approach is required for accurate characterization of the broader cancer ecosystem
- The ImmunoID NeXT platform consolidates multiple biomarker assays into one with the ability to detect neoantigens, characterize the immune repertoire and identify novel biomarker signatures from a single sample
- Featuring a case study demonstrating the ability of this immunogenomics profiling platform to uncover tumor escape mechanisms

ERIN NEWBURN, Associate Director, Field Applications Scientist, Personalis
Day One: 19 February 2020

Stream 1: Biomarkers in Drug Discovery & Development – Therapeutic Areas: Oncology & Immunology
Conference Room: Charter 4
Stream Chair: Suso Platero, Global Leader Precision Medicine, Head Biomarker Solution Center, Covance

Stream Keynote Address: Tumour Localised Activation Of The Immune System Using PRS-343, A HER2/4-1BB Bispecific Molecule, In Patients With HER2-Positive Malignancies
- PRS-343 is the first molecule of its kind to demonstrate encouraging evidence of safety and clinical benefit with a correlative PD effect in a heavily pre-treated population
- These initial data suggest that PRS-343, the first 4-1BB bispecific to enter clinical development, merits further investigation in clinical trials

Markus Zettl, Director, Immuno-Oncology, Pieris Pharmaceuticals

Stream 2: Biomarkers for Detection, Monitoring & Diagnosis
Conference Room: Exchange 6&7
Stream Chair: Senior Representative, ARC Regulatory

Stream Keynote Address: Advances in Precision Medicine To Enable a Patient Centric Approach
- Exploring how Precision Medicine is used in the development of targeted therapies
- Exemplifying the patient benefit of Precision Medicine through two case studies in Oncology
- Enabling the future of Precision Medicine with application across all therapy areas

Mark Rrockett, Vice President & Head of Precision Medicine Diagnostic Development, AstraZeneca

Stream 3: Biomarkers for Clinical Development
Conference Room: Exchange 11
Stream Chair: Dan Sikkema, Vice President, Biopharmaceutical and Bioanalytical Services, Quanterix

Stream Keynote Address: Patient And Target Selection in A Personalized Multi-Target Adoptive Cell Therapy Trial
- ACTolog® (IMA101) is a fully personalized multi-target adoptive cell therapy approach designed to use autologous T-cell products that are redirected towards multiple novel tumor targets identified by Immatics' proprietary XPRESSIDENT® technology platform
-IMATECTM is an investigational diagnostic quantitative reverse transcription PCR (qRT-PCR) device that is used to analyze mRNA expression of multiple tumor-associated target genes in patient fresh tumor biopsies
- Expression thresholds can be determined for each target by combining quantitative HLA ligandomics and RNAseq

Arun Sattelli, Associate Director Target Biomarkers, Immutas

Stream 4: Biomarker Candidates To Qualified Markers – Approaches And Case Studies
Conference Room: Exchange 4&5
Stream Chair: Hugh Ilyine, Co-Founder, Chief Executive Officer and Director, Merck-Destina

Stream Keynote Address: Biomarker Candidates To Qualified Markers – Approaches And Case Studies
- Biomarker identification and prioritization approaches
- Qualifying biomarkers – challenges and rewards
- Therapeutic case studies

Katherine Call, Senior Director and Head, Proteogenomics, Sanofi

Exhibition Area: The Gallery & Charter 1 – 3
Morning Coffee & Refreshments, One To One Meetings x4, Poster Presentation Sessions

Translating Cancer Research Into Novel Therapies
- Biomarker strategies for identification of the right patients for targeted therapy
- Biomarkers for monitoring drug response
- Translational analysis of mechanisms of resistance to guide future combination strategies

Liz Harrington, Executive Director, Head of Translational Science UK, AstraZeneca

Molecular Screening And Early Detection For Diagnosing Hereditary Non-Polyposis Colorectal Cancer
- Biomarkers for cancer early detection
- Analytical and clinical validation of biomarkers
- Recent success in cancer biomarkers for early detection
- Challenges in measuring the clinical utility of biomarkers

Sudhir Srivastava, Chief, Cancer Biomarkers Research Group, NIH

Selective Expansion Of Regulatory T Cells By A Novel IL-2 Conjugate, NKTR-358, Being Developed For The Treatment Of Autoimmune Diseases
- NKTR-358 is a polyethylene glycol (PEG) conjugate of recombinant human IL-2 with increased half-life versus rHL-2
- The first-in-human single-ascending dose study of NKTR-358 demonstrates selective, prolonged, dose-dependent induction of regulatory T cells over conventional T cells and NK cells
- Clinical results in healthy volunteers provide strong support for studying NKTR-358 as a new therapeutic in inflammatory and autoimmune diseases

Christie Fanton, Senior Director, Translational Research, Nektar Therapeutics

Utilising Genomic Technologies As Predictive Biomarkers In Drug Targets For Immunotherapy
- Development and use of MSI testing
- Tumor Mutation Burden: development and challenges as a clinical biomarker
- Beyond BRCA in PARP therapies

Deepi Aurora-Garg, Executive Director, Companion Diagnostics, MSD
<table>
<thead>
<tr>
<th>Time</th>
<th>Stream</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50</td>
<td>STREAM 1</td>
<td>Clinical Trial Assay &amp; CDx Development In The Era Of Precision Medicine – Planning For Success</td>
<td>LEOONA GALLIGAN, Vice President of UK Operations, Almac Diagnostic Services</td>
<td>Almac Diagnostic Services</td>
</tr>
<tr>
<td>12:20</td>
<td>STREAM 2</td>
<td>Advancing Biomarker Discovery Through Emerging Technologies</td>
<td>GAYLE MARSHALL, Lead Scientist, Biomarkers, Medicines Discovery Catapult</td>
<td>Medicines Discovery Catapult</td>
</tr>
<tr>
<td>12:50</td>
<td>STREAM 3</td>
<td>Defining The Genetic And Environmental Determinants Of Immune Response Variability For Clinical Biomarker Development</td>
<td>DARRAGH DUFFY, Scientific Director, LabEx Milieu Interieur, Institut Pasteur</td>
<td>Institut Pasteur</td>
</tr>
<tr>
<td></td>
<td>STREAM 4</td>
<td>OncoPanel™ Phenotypic Cell-Based Profiling For Predictive Genomic Biomarker Discovery</td>
<td>ALASTAIR KING, Scientific Director, Eurofins Discovery</td>
<td>Eurofins Discovery</td>
</tr>
</tbody>
</table>

**Early Biomarker Development For Cancer Therapeutics**
- Biomarker definitions and their potential in early development
- Strategy to focus on informative biomarkers that lead to conclusive trials or prepare later development
- Examples of predictive biomarkers (potential CDs), biomarkers of target engagement and early disease progression

**Pre-Analytical Processes In Medical Diagnostics: New Requirements And Standards**
- IVDR requirements for Biomarkers development
- Pre-analytical ISO standards for medical diagnostics
- Quality control of biological resources
- Biomarkers validation requirements
- Clinical evaluation requirements

**Best Practices For Incorporating Potentially Predictive Biomarkers In Early Clinical Development**
- Strategies for incorporation of patient selection hypothesis testing in early clinical development: prospective selection vs. stratification vs. retrospective testing
- Immunohistochemical (IHC) methods, assay development and validation
- Genetic hypotheses, implementation, integration with protein based methods; methods beyond traditional genetics and IHC

**Utilising Genetic Biomarkers To Help Predict Efficacy And Better Understand Adverse Events**
- Overview of what we’ve learned from previous PGx efforts
- How that has shaped our current PGx strategy
- How will Genetics impact future efforts

**Utilising Genetic Biomarkers To Help Predict Efficacy And Better Understand Adverse Events**
- Overview of what we’ve learned from previous PGx efforts
- How that has shaped our current PGx strategy
- How will Genetics impact future efforts

**Best Practices For Incorporating Potentially Predictive Biomarkers In Early Clinical Development**
- Strategies for incorporation of patient selection hypothesis testing in early clinical development: prospective selection vs. stratification vs. retrospective testing
- Immunohistochemical (IHC) methods, assay development and validation
- Genetic hypotheses, implementation, integration with protein based methods; methods beyond traditional genetics and IHC

<table>
<thead>
<tr>
<th>Time</th>
<th>Stream</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>STREAM 5</td>
<td></td>
<td>GAYLE MARSHALL, Lead Scientist, Biomarkers, Medicines Discovery Catapult</td>
<td>Medicines Discovery Catapult</td>
</tr>
<tr>
<td></td>
<td>STREAM 6</td>
<td></td>
<td>DARRAGH DUFFY, Scientific Director, LabEx Milieu Interieur, Institut Pasteur</td>
<td>Institut Pasteur</td>
</tr>
<tr>
<td></td>
<td>STREAM 7</td>
<td></td>
<td>ALASTAIR KING, Scientific Director, Eurofins Discovery</td>
<td>Eurofins Discovery</td>
</tr>
</tbody>
</table>

**Exhibition Area: The Gallery & Charter 1 – 3**
Lunch, One To One Meetings x3, Poster Presentation Sessions
Bioinformatics In Biomarker Discovery

- Biomarkers are a core part of modern drug development and clinical practise. Leading to more accurate diagnosis and prognosis of diseases, and allowing treatments to be tailored to individual patients.
- In this domain, vast amounts of ‘omics data are being generated, which provides computational challenges to analyze and interpret the data. Careful planning and use of appropriate bioinformatics tools and methodologies are key to identifying relevant biological signals.
- Fios Genomics is a bioinformatics service provider specialising in this area.

ADRIAN CARR, Bioinformatics Team Leader, Fios Genomics

Enhanced Biomarker Discovery And Validation Using TMT® Proteomics

- Recent developments in proteomics are making it an essential tool supporting drug development. Broader profiling of disease mechanisms that go beyond relatively crude genetic drivers is opening up raft’s of new targets, whilst deepening proteome coverage of peripheral fluids mean we can find disease-relevant biomarkers for monitoring treatment effect more readily.
- Proteome Sciences has been at the forefront of driving the introduction of Tandem Mass Tags®, invention of MS3 quantification and development of global profiling tools such as SynQuant® and TMCalibrator®. Operating from 10,000 sq ft facility in Frankfurt, Germany, with ISO 9001:2015 and GCLP (for targeted assays) we provide our clients with a highly flexible and high-quality proteomics service that allows them to be more informed and efficient throughout the drug development process.
- During this presentation I will describe our core technologies with examples of their application across a number of therapeutic areas. Applications include detailed analysis of underlying disease mechanisms to discover and contextualise therapeutic targets, monitoring of drug mechanism in experimental systems and the discovery and validation of circulating, disease-related biomarkers.

IAN PIKE, Chief Scientific Officer, Proteome Sciences

Finding The Needle In The Haystack: Supporting Clinical Trials With Measurable/Minimal Residual Disease (MRD) Detection

- Measurable/minimal residual disease (MRD) as a biomarker and surrogate endpoint for clinical trials.
- Advantages/disadvantages of several techniques used for detecting MRD.
- Case review and MRD capabilities at Hematogenix.

HIKMAT DAGHESTANI, Director, Biomarker Discovery & Development, Hematogenix

Precision Metabolomics: A Leading Tool For Biomarker Discovery

Researchers continue to identify and refine approaches to detect and characterize biomarkers to support precision diagnostics, drug responsiveness and disease progression. Traditional clinical and diagnostic assays are limited in the results and type of compounds that can be detected and measured in one test. Therefore, clinicians are presented with the challenge that a single biomarker is not always dependable for diagnostic, prognostic or predictive purposes. Interest continues to grow in untargeted metabolomics as the technology provides reliable insights on phenotypic changes, making the ‘omic an excellent option for discovering clinically relevant biomarkers. These small molecules support the process of diagnosis, drug efficacy, toxicity and more, leading clinicians and researcher to increase their reliance on metabolomic insights for their decision-making process. This talk will profile case studies based on Metabolon’s Precision Metabolomics™ platform that have led to biomarker discovery for appropriate diagnosis and predicting patient response to therapeutics.

VINAY PAWAR, Field Application Scientist, Metabolon

Exploiting RNA In Liquid Biopsies For Precision Medicine Purposes

- Biofluids (beyond plasma) are rich sources of messenger RNAs, circular RNAs and microRNAs.
- Currently, pre-analytical standardization (RNA extraction, blood collection tube, time points) is key to achieve reliable results.
- Selected case studies show applicability of liquid biopsy based RNA profiling.

JON VANDENOMPELE, Professor of Functional Cancer Genomics and Applied Bioinformatics, Ghent University and Co-Director and Chief Scientific Officer, Biogazelle
Quantitative Systems Pharmacology (QSP), An Approach To Mechanistic Modelling Of The Interaction Between Biomarkers, Disease Pathophysiology And Drug Pharmacology With Case Studies In Autoimmune Disease

- Learn how can QSP can be an integral component of hypothesis generation and testing in pharmaceutical R&D
- What are the requirements for data collection, model building, model calibration and model validation in QSP?
- Demonstration of how a QSP autoimmune disease model can be used to generate useful and actionable quantitative hypotheses for clinical development

TAREK LEIL, Head - Quantitative Clinical Pharmacology, Bristol-Myers Squibb

Biomarker Discovery: Flow Cytometry, AI And Liquid Biopsy

- Detecting the presence and clinical significance of prostate cancer using Machine Learning analysis of peripheral blood phenotyping data
- The theranostic potential of membrane Hsp70 in cancer: Development of a liquid biopsy and an approach for isolating circulating tumour cells

GRAHAM POCKLEY, Director & Professor of Immunobiology, Nottingham Trent University and Chief Executive Officer, multimune GmbH

Clinical Biomarker Method Development And Fit-For-Purpose Validation In Support Of Drug Development: Challenges, Learnings And Opportunities

- A high degree of emphasis is being placed within the area of biomarker research, as biomarker data are often critical for understanding biological target engagement, efficacy, dose-response relationship, and PK/PD modeling. For clinical biomarker research, one of the goals is establishing scientifically meaningful and reproducible assays to generate reliable data that are suitable for strategic decision-making for a drug development program. The analytical method and data must provide an ability to differentiate between normal and disease population and evaluate the progression from one state to another
- This presentation discusses in detail the challenges to develop reliable biomarker bioanalytical assays, as well as the methods developed at Pfizer to overcome these issues. The differences between PK and biomarker assays will be also introduced, including platform selection, sample preparation strategies, standard curve and QC preparation, and regulation consideration. The application of fit-for-purpose method validation notion when developing and validating clinical biomarker assays will additionally be addressed. Three unique clinical case studies will be introduced to facilitate the discussion

JENNY ZHANG, Associate Director, Clinical Biomarker Assay Specialist, Pfizer

Patient Selection Biomarkers In Preclinical Drug Discovery: Application To DNA Damage Response Agent In Cancer Therapy

- Introduction on the concept of patient selection biomarkers
- Impact on drug discovery success
- Introduction to DNA damage response targeting anti-cancer treatments
- Example of successful patient selection biomarkers: HRD and PARPi
- Approaches to identify patient selection biomarkers:
  - Screening approaches: cell line panels, mutagenesis, siRNA & CRISPR/Cas9
  - Validation approaches: KD, chemical perturbation & isogenic pairs
- Translation to preclinical studies: identification of the correct animal models
- Summary and final remarks

MARCO RANZANI, Senior Scientist, Artios Pharma

Delegates are welcome to attend the co-located presentations
DAY ONE: 19 FEBRUARY 2020

STREAM 1
BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT – THERAPEUTIC AREAS: Oncology & Immunology
Conference Room: Charter 4

Innovative Solutions For Discovery And Translational Biomarker Strategies
GRAEME CLARK, Vice President of Bioanalysis & DMPK, Aquila BioMedical, A Concept Life Sciences Company

16:50 - 17:20

STREAM 2
BIOMARKERS FOR DETECTION, MONITORING & DIAGNOSIS
Conference Room: Exchange 6&7

Comprehensive Biomarker Identification With High-Parameter Research From Cell Types To Tissue: Analyse >50 Functional And Phenotypic Markers Simultaneously On The Helios And Hyperion™ Imaging System, Powered By CyTOF® Technology
ROBERTO SPADA, Business Development Manager, Mass Cytometry Franchise, EMEA, Fluidigm

17:20 - 18:50

STREAM 3
BIOMARKERS FOR CLINICAL DEVELOPMENT
Conference Room: Exchange 11

Quantitative Spatial Cytometry For Biomarker Discovery & Validation
JON WATERMAN-SMITH, Director, European Business Development, Canopy Biosciences

18:50 - 19:40

WORKSHOP
Biomarker Qualification: Technical Validation And Regulatory Aspects
Conference Room: Charter 4

Workshop: Biomarker Qualification: Technical Validation And Regulatory Aspects
Moderator: JOHN ALLINSON, Vice President - Biomarker Sciences, Immunologix Laboratories

19:40 - 20:30

STREAM 4
PART 2: DATA ANALYSIS OF LARGE GENOMIC SAMPLES
Conference Room: Exchange 4&5

 Seven Habits Of Highly Effective Biomarkers
WIM VAN CRIEKINGE, Co-Founder and Board Member, BioLizard

20:30 - 21:20

Exhibition Area: The Gallery & Charter 1 – 3
Networking Drinks & End Of Day One

21:20 - 22:10

Congress Dinner: Old Trafford
### Table 1: Preventing Past Mistakes In Biomarkers

Moderator: FABIO RIGAT, Director, Oncology Biostatistics, Janssen

### Table 2: Immunoassay Development For Biomarker Research And Diagnostic Development

Moderator: THOMAS JOOS, Deputy Managing Director, NMI Natural and Medical Science Institute at the University of Tübingen

### Table 3: Directors Club Closed Door Session: Regulatory Issues For Diagnostic Devices Post-Brexit

Moderator: ERIK VOLLEBREGT, Partner, Axon Lawyers

### Table 4: Untargeted Drug Biomarker Discovery & Distribution For (Early) Safety And Target Engagement By MALDI Tissue Mass Spectrometry Imaging – An Underestimated Tool In Drug Discovery

Moderator: BOGDAN MUNTEANU, DMPK – Imaging Mass Spectrometry Scientist, Sanofi

### Table 5: Translation Of Biomarkers: Improvement Of Robustness And Reproducibility And The Role Of Industry

Moderator: ANDREAS SCHERER, Research Coordinator – Business Development, Institute for Molecular Medicine Finland (FIMM)

### Determining Correct Biomarkers For Drug Development

- How to evaluate biomarkers throughout drug development phase
- How to evaluate biomarkers around different therapeutic areas
- Biomarkers by organ systems

TUULIA HUHTALA, Head of Biomarkers and Molecular Imaging, CNS Discovery, Charles River

### Novel Single Molecule Counting (SMC™) Of MicroRNA By A PCR Free Method

- DESTINA Genomics = Revolutionary PCR free direct detection of microRNAs in biological samples
- The Merck Millipore SMCx-Pro offers highly sensitive protein AND microRNA detection on the same machine
- No extraction, purification, refrigeration needed from sample prep to quantitative analysis
- Detect both canonical microRNAs as well as isoMirs

HUGH ILYINE, Co-Founder, Chief Executive Officer and Director, Merck-Destina

### S-Plex Kits, fg/mL Detection On The MSD Platform In Your Hands

- Introduction to MSD's S-PLEX Kits
- Simple protocols and diverse matrix capability
- Spectacular sensitivity

CHRIS WALKER, Vice President of Scientific Support, Meso Scale Discovery

---

**DAY TWO: 20 FEBRUARY 2020**

**Exhibition Area: The Gallery & Charter 1 – 3**

**Morning Coffee & Refreshments, One To One Meetings x4, Poster Presentation Sessions**
Fluid Biomarkers For Parkinson’s Disease

- Aggregated alpha-synuclein in the brain is the hallmark of Parkinson’s disease (PD)
- Total and phosphorylated alpha-synuclein in the CSF have limited value as PD biomarkers
- Monitoring the seeding activity of aggregated alpha-synuclein in the CSF is a promising approach for PD diagnosis and currently explored as a potential disease progression marker
- Multicandidate approaches identify new biomarker candidates in the CSF and plasma of PD patient

ROLAND HEYM, Principle Research Scientist, AbbVie Deutschland GmbH & Co. KG

Enabling Patient Centricity In Clinical Development Through At Home Sample Collection For Biomarkers Translating Exploratory Biomarkers Into Clinical Trials

Traditional approaches for measurement of drug exposure and biomarkers in clinical trials involves having the patient travel to a clinical site for collection of venous blood. This puts a burden on the patient while also limiting the opportunities for assessment of drug exposure or other measurements to these clinical visits. The ability to collect samples at home would provide a more patient-centric approach. At home collection would provide benefit for more frequent assessment of drug exposure and biomarkers of efficacy and toxicity. This talk will share results from recent pilot studies assessing at home sampling technologies for biomarker analysis.

BRAD EVANS, Associate Principal Scientist, MSD

Translating Exploratory Biomarkers Into Clinical Trials

- Translational approach
- Introduction into the Biomarker categories
- How to prepare a biomarker strategy
- How to implement exploratory biomarkers in a clinical trial

MARIANNE SCHEEL FJORDING, Scientific Director, Translational Science, Novo Nordisk

Implementation Of Simple Plex Technologies For Biomarker Analysis

- Direct transfer of traditional ELISA’s to Simple Plex
- Evaluation of the home-brew applications
- Beta-Test of the commercial NF-L cartridge for Plasma applications

MATHIAS DROESCHER, Senior Scientist, AbbVie Deutschland GmbH & Co. KG

Ultra-Sensitive Biomarker Detection: Taking New Technologies Into The New Decade

- Ultra-sensitive immunoassay methods of biomarker detection can provide insight into early or pre-symptomatic disease detection and progression, or give provide value insights into the efficacy and biology of therapeutic drugs and their targets
- In order to detect biomarker concentrations below pg/mL levels, highly specialized platforms have evolved over the past decade to fill this niche. For effectiveness within regulated environments and CRO labs, an emphasis must be placed on these platforms performing robustly and reproducibly
- One of the latest such platforms, the Quanterix HD-X, integrates existing assay Simoa technology but takes steps to address the question of robustness. This presentation will explore the utility, advantages, and disadvantages, of implementing the Quanterix HD-X into a regulated CRO. From performing commercial kits to bespoke biomarker assay development and computer systems validation

MATHIAS DROESCHER, Senior Scientist, AbbVie Deutschland GmbH & Co. KG

Solution Provider Presentation

Nu.Q™ Capture – Isolation And Profiling Of Tumour Derived Circulating Cell Free Nucleosomes

- Development of an efficient approach to immunocapture of cell free circulating nucleosomes
- Enrichment of tumour derived, circulating cell free nucleosomes and associated DNA from background nucleosomes of haematopoietic origin
- Clinical applications for Mass spectrometry, immunonocaul and sequencing based analysis of cell free, circulating tumour nucleosomes

MARK ECCLESTON, Business Development Director, Volition

Development Of A Novel Next-Generation Sequencing (NGS)-Based Assay For Measurable Residual Disease (MRD) In FLT3-ITD AML And Its Potential Clinical Applications

- A custom-designed PCR-based fragment analysis FLT3-ITD assay was developed to select acute myeloid leukemia (AML) patients with FLT3-ITD mutations for late-phase clinical trials at Daiichi Sankyo
- The presence of MRD in patients with AML who are in morphologic remission has been shown to be a powerful predictor of eventual relapse
- Using isolated genomic DNA from bone marrow aspirates or whole-blood samples, PCR primers flanking exons 14 and 15 of the FLT3 gene were designed, highly diverse NGS libraries were generated, and a sequencing depth >100,000x was achieved for this FLT3-ITD MRD assay
- Clinical utility validation results of this MRD assay will be presented; this assay could be used to define the depth of remission, identify persistent disease, and help guide decision making in the use of FLT3 inhibitors as continuation therapy

KEN CHANG, Director, Clinical Biomarkers, Daiichi Sankyo

Ultra-Sensitive Biomarker Detection: Taking New Technologies Into The New Decade

- Development of an efficient approach to immunocapture of cell free circulating nucleosomes
- Enrichment of tumour derived, circulating cell free nucleosomes and associated DNA from background nucleosomes of haematopoietic origin
- Clinical applications for Mass spectrometry, immunonocaul and sequencing based analysis of cell free, circulating tumour nucleosomes

MATHIAS DROESCHER, Senior Scientist, AbbVie Deutschland GmbH & Co. KG

Solution Provider Presentation

Nu.Q™ Capture – Isolation And Profiling Of Tumour Derived Circulating Cell Free Nucleosomes

- Development of an efficient approach to immunocapture of cell free circulating nucleosomes
- Enrichment of tumour derived, circulating cell free nucleosomes and associated DNA from background nucleosomes of haematopoietic origin
- Clinical applications for Mass spectrometry, immunonocaul and sequencing based analysis of cell free, circulating tumour nucleosomes

MARK ECCLESTON, Business Development Director, Volition

Development Of A Novel Next-Generation Sequencing (NGS)-Based Assay For Measurable Residual Disease (MRD) In FLT3-ITD AML And Its Potential Clinical Applications

- A custom-designed PCR-based fragment analysis FLT3-ITD assay was developed to select acute myeloid leukemia (AML) patients with FLT3-ITD mutations for late-phase clinical trials at Daiichi Sankyo
- The presence of MRD in patients with AML who are in morphologic remission has been shown to be a powerful predictor of eventual relapse
- Using isolated genomic DNA from bone marrow aspirates or whole-blood samples, PCR primers flanking exons 14 and 15 of the FLT3 gene were designed, highly diverse NGS libraries were generated, and a sequencing depth >100,000x was achieved for this FLT3-ITD MRD assay
- Clinical utility validation results of this MRD assay will be presented; this assay could be used to define the depth of remission, identify persistent disease, and help guide decision making in the use of FLT3 inhibitors as continuation therapy

KEN CHANG, Director, Clinical Biomarkers, Daiichi Sankyo

Development Of A Novel Next-Generation Sequencing (NGS)-Based Assay For Measurable Residual Disease (MRD) In FLT3-ITD AML And Its Potential Clinical Applications

- A custom-designed PCR-based fragment analysis FLT3-ITD assay was developed to select acute myeloid leukemia (AML) patients with FLT3-ITD mutations for late-phase clinical trials at Daiichi Sankyo
- The presence of MRD in patients with AML who are in morphologic remission has been shown to be a powerful predictor of eventual relapse
- Using isolated genomic DNA from bone marrow aspirates or whole-blood samples, PCR primers flanking exons 14 and 15 of the FLT3 gene were designed, highly diverse NGS libraries were generated, and a sequencing depth >100,000x was achieved for this FLT3-ITD MRD assay
- Clinical utility validation results of this MRD assay will be presented; this assay could be used to define the depth of remission, identify persistent disease, and help guide decision making in the use of FLT3 inhibitors as continuation therapy

KEN CHANG, Director, Clinical Biomarkers, Daiichi Sankyo

Development Of A Novel Next-Generation Sequencing (NGS)-Based Assay For Measurable Residual Disease (MRD) In FLT3-ITD AML And Its Potential Clinical Applications

- A custom-defined PCR-based fragment analysis FLT3-ITD assay was developed to select acute myeloid leukemia (AML) patients with FLT3-ITD mutations for late-phase clinical trials at Daiichi Sankyo
- The presence of MRD in patients with AML who are in morphologic remission has been shown to be a powerful predictor of eventual relapse
- Using isolated genomic DNA from bone marrow aspirates or whole-blood samples, PCR primers flanking exons 14 and 15 of the FLT3 gene were designed, highly diverse NGS libraries were generated, and a sequencing depth >100,000x was achieved for this FLT3-ITD MRD assay
- Clinical utility validation results of this MRD assay will be presented; this assay could be used to define the depth of remission, identify persistent disease, and help guide decision making in the use of FLT3 inhibitors as continuation therapy

KEN CHANG, Director, Clinical Biomarkers, Daiichi Sankyo

Development Of A Novel Next-Generation Sequencing (NGS)-Based Assay For Measurable Residual Disease (MRD) In FLT3-ITD AML And Its Potential Clinical Applications

- A custom-defined PCR-based fragment analysis FLT3-ITD assay was developed to select acute myeloid leukemia (AML) patients with FLT3-ITD mutations for late-phase clinical trials at Daiichi Sankyo
- The presence of MRD in patients with AML who are in morphologic remission has been shown to be a powerful predictor of eventual relapse
- Using isolated genomic DNA from bone marrow aspirates or whole-blood samples, PCR primers flanking exons 14 and 15 of the FLT3 gene were designed, highly diverse NGS libraries were generated, and a sequencing depth >100,000x was achieved for this FLT3-ITD MRD assay
- Clinical utility validation results of this MRD assay will be presented; this assay could be used to define the depth of remission, identify persistent disease, and help guide decision making in the use of FLT3 inhibitors as continuation therapy

KEN CHANG, Director, Clinical Biomarkers, Daiichi Sankyo
DAY TWO: 20 FEBRUARY 2020

Join The Flow Revolution: MACSQuant® Tyto® Cell Sorter For Closed Multiparametric Cell Sorting
- Please join us for this informative seminar covering the features and benefits of the MACSQuant® Tyto®
- Miltenyi Biotec, a world leader in flow cytometry solutions, now offers an opportunity to expand cell sorting capabilities with innovative microchip-based technology of the MACSQuant® Tyto® Cell Sorter
- The unique features of the system improve cell viability and functionality all within a sterile, closed system
- Come and discover how the MACSQuant® Tyto® Cell Sorter and innovative REALease cell staining reagents could revolutionise your cells sorting capabilities

CHARLOTTE EGAN, Flow Cytometry Application Specialist Manager, Miltenyi Biotec Ltd.

ANGELA VASATURO, Senior Field Application Scientist, Ultivue

JOSHUA PICKERING, Senior Analyst, Intertek

Panellists To Be Announced Shortly

PHENOTYPING THE TUMOR MICROENVIRONMENT WITH ADVANCED TISSUE-BASED MULTIPLEXING ASSAYS
- Better understand the complexity of the tumor microenvironment (TME)
- Introduction to InSituPlex® DNA-barcoding and antibody staining technology for multiplex fluorescence IHC
- How to make use of multi-parameter data within the TME - spatial mapping, high and low expression, and co-localization of markers on individual cells

ANGELA VASATURO, Senior Field Application Scientist, Ultivue

Validation Of A Biomarker Panel In Different Matrices - Challenges And Approaches
- Clinical biomarkers measuring the inflammatory response measured by immunoassay platforms
- Discussion on how endogenous levels across multiple clinical matrices impacts the development process
- Evaluation of the approaches taken for fit for purpose validation
- Reflection on the context of use of the biomarker assays

JOSHUA PICKERING, Senior Analyst, Intertek

Solution Provider Presentation
- Patient stratification pre-and post-diagnosis
- New tools for drug developers in neurodegenerative diseases
- Immuno-Oncology (prediction and monitoring of treatment effect)
- Future outlooks in the ultra-sensitive biomarker arena

DAN SIKKEMA, Vice President CRO and Bioanalytical Services, Quanterix

Title To Be Confirmed

Ultra-Sensitive Quantitation Of Biomolecules And Advancements In Precision Health Monitoring
- Reserved for IRBM

DAN SIKKEMA, Vice President CRO and Bioanalytical Services, Quanterix

Senior Representative, HistologiX

Delegates are welcome to attend the co-located presentations

Exhibition Area: The Gallery & Charter 1 – 3
Lunch, One To One Meetings x3, Poster Presentation Sessions | Sponsored by Fluidic Analytics
### WORKSHOP: Integrating Different Biomarker Data For Successful Drug And Diagnostic Development

**Conference Room: Charter 4**

**Stream Chair:** TBA

#### Workshop: Integrating Different Biomarker Data For Successful Drug And Diagnostic Development

The workshop will feature short presentations on managing and integrating different types of biomarker data for successful drug and diagnostic development.

**Case Study 1: BMK TOOLS®: Bridging Biomarkers From The Lab To The Patient**

- Avesan is the French national alliance for life sciences and health. One of the objectives of Avesan is to develop tools to help scientists to valorize their research. BMK TOOLS® was created to help everyone understand and master the different development stages of a biomarker, thus enabling various communities to draw upon a common language.
- BMK TOOLS® is designed for all researchers and startups coming from the academic world faced with a project for the development of a biomarker, across all therapeutic areas. This site brings together several tools. 1) An educational module “Learn” in which there is a fact sheet at every development stage of a biomarker and its detection test; 2) An application module “Position a project” in which an online questionnaire is made available.
- Since the interest in the development of relevant biomarkers which lead to better care for patients goes beyond the national framework, EIT Health (branch of EIT, European Institute for Innovation and Technology, a body of the European Commission), joins BMK TOOLS® for the future dissemination of this tool in Europe.
- Based upon a project already reviewed by BMK TOOLS, we will explain the added value of our tool for the discovery of biomarkers.

**MARIE ANSON, BMK Tools Coordinator, INSERM**

**Case Study 2: Clinical Imaging Data**

- Introduction to imaging methods and applications to drug development.
- Imaging data and how image-based biomarkers are extracted.
- Opportunities to integrate imaging with other data types.
- Future directions to maximise value from imaging data.

**PHIL MURPHY, Head, Clinical Imaging, GlaxoSmithKline**

**Case Study 3: Integrating Biomarker Data For CDx Development**

**CAITRIONA HOLOHAN, Operations Team Leader, Almac Diagnostic Services**

### Panel Discussion: Learning And Challenges In Integrating Data

**Panellists As Above**

---

### BIOMARKERS FOR PRECLINICAL TO CLINICAL DEVELOPMENT

**Conference Room: Exchange 11**

**Stream Chair:** Senior Representative, Intertek

#### Drug And Untargeted Biomarker Distribution For Target Engagement And Investigative Toxicology (iTOX) By Tissue Imaging MS At Sanofi Global DMPK: A Technological And Strategic Introduction

- Untargeted Biomarker Discovery
- Tissue Drug/Biomarker Distribution
- MALDI Tissue Imaging Mass Spectrometry
- Preclinical Safety
- 3R Strategy for Pre-Clinical Biomarker Discovery
- Target Engagement
- Early-Tox

**BOGDAN MUNTEANU, DMPK – Imaging Mass Spectrometry Scientist, Sanofi**

#### Development Of Pharmacodynamic Biomarkers Associated To The Phase 2 Clinical Stage Anticancer Drug ABTL0812

- Preclinical studies to investigate the mechanism of action of ABTL0812
- Applying the studies in the clinics as PD biomarkers

**MARC YESTE-VELASCO, Director of Translational Research, Ability Pharmaceuticals, SL**

#### Preclinical Experience Using Luminex-Based Immunoassays

- Assay performance plays a critical role when applying safety biomarkers in drug discovery.
- Multiplex Luminex-based immunoassays offer several advantages over single-analyte assays, but also give rise to specific analytical challenges.
- Case examples will be presented.

**TIM ERLENS, Senior Scientist, Non-Clinical Safety, Janssen**

---

### GENOMIC BIOMARKERS FOR PRECISION MEDICINE AND CLINICAL PRACTICE

**Conference Room: Exchange 4 & 5**

**Stream Chair:** MARK ECCLESTON, Business Development Director, Volition

#### Pharmacogenomic Biomarkers And Clinical Implementation

- Patient selection
- Biomarker validation
- Clinical decision support system
- Patient and staff acceptance of health innovation
- Barriers to implementation

**ANA ALFIREVIC, Professor of Pharmacology and Personalised Medicine, University of Liverpool**

#### Workshop: Genomic Biobanking To Facilitate Precision Medicine

- The scope of this field: past and future perspective
- Novel target discovery through genomic biobanking
- Role of biobanks in translational medicine
- Clinical implementation of genomic data for precision medicine

**MODERATOR: PATRICK KLEYN, Vice President, Translational R&D, Rhythm Pharmaceuticals**

**INVITED PANEILLISTS:**

- GEORGES DAGHER, Research Director, INSERM
- JOHN WISE, Executive Director, Pistoia Alliance

---

### Exhibition Area: The Gallery & Charter 1 – 3

**Afternoon Coffee & Refreshments, Poster Presentation Sessions**
**Blood Biomarkers In Neurological Disorders: Utility In Disease Progression And Patient Response**

- The Challenge of Identifying Biomarkers for Patient Selection, Stratification & Therapeutic Response
- Blood Biomarkers at the Nexus of Disease Progression & Therapeutic Response
  - Leveraging Enabling Technologies to Expedite the Discovery & Development of Disease-Modifying Therapeutics

**Statistical Issues In Biomarker Validation**

- Review of some statistical methods relevant for validation of different types of biomarkers (prognostic, predictive and surrogate) for use in e.g. clinical trials or precision medicine.
- Presentation of some illustrative examples from Asthma and Chronic Obstructive Pulmonary Disease (COPD).
- Discussion of various sources of data that can be used for validation of biomarkers
- Discussion of relevant guidance documents relevant to validation of biomarkers
- Some simulation results addressing certain statistical issues: (i) Low statistical power (ii) Confusion of prognostic and predictive biomarkers (iii) Use and misuse of covariates (iv) Using cut points vs. using continuous data. (v) The need for pragmatism (vi) Absence of Consensus
- Discussion of additional caveats and presenting some solutions: (a) data involving repeated measures (b) multiplicity issues when e.g. handling multiple biomarkers. (c) selection bias in meta analyses (d) Confounding in observational data

**Clinical Proteomics Enters Clinical Trials: A Generic GCP-Compliant Workflow For The Routine Analysis Of Patient-Derived FFPE Samples By Quantitative Mass Spectrometry**

- Quantitative mass spectrometry is becoming a more routine technique for the analysis of human clinical samples
  - Gradual acceptance by the regulators
- Quantitative mass spectrometry represents a time- and cost-effective method to build assays suitable for hypothesis testing
  - Inescapable if reference antibodies are not available
  - Amenable to multiplexed readouts
- I will show our latest test case studies and review our current experience in developing GCP-compliant protocols for the routine analysis of FFPE tissue samples at CROs

**Epigenetic Clocks As Most Accurate Biomarkers For Ageing And Age-Related Disease**

- The aging population challenge
- The 9 cellular and molecular hallmarks of aging
- Epigenetic modifications across human lifespan led to the discovery of high-resolution and most accurate biomarkers of aging: epigenetic clocks
- By harnessing these epigenetic clocks, at Shift Bioscience we discovered small molecules reversing age by 40% in mice, and increasing human skin cells proliferation

**Using The Microbiome As A Biomarker: New Technologies And Approaches**

- The need and challenges in microbiome-based biomarker discovery
- Using a novel cloud based computational approach utilizing machine learning to identify biomarkers
- Sharing examples of biomarker discovery

**Circulating Biomarkers For Cancer Diagnosis, Prognosis And Prediction**

- Circulating tumour biomarker has great potential in cancer diagnosis and precision medicine
- CTCs are valuable for cancer diagnosis, treatment prediction/monitoring
- CTC gene expression profiling enhance CTC number analysis for prostate cancer diagnosis

---

**Delegates are welcome to attend the co-located presentations**
Manchester Central
Petersfield, Manchester, UK, M2 3GX
Tel: +44 (0)161 834 2700

The Biomarkers Series UK 2020 will once again be held in the award-winning Manchester Central. This ever popular historic venue is converted from the former Manchester Central railway station, known for its distinctive architecture - the second largest railway station roof span in the United Kingdom.

The Congress will be held in the Charter Suites and Gallery area. Please use the Charter Foyer entrance, which is located to the right of the venue’s main entrance. The hotel is easily accessible by rail, car and air. Detailed travel directions can be found at: oxfordglobal.co.uk/biomarkers-series-uk/plan-your-visit/

Located in the heart of the city, Manchester Central is served by two Metrolink tram stops, both of which are under a five-minute walk from the venue, allowing visitors to explore the “second city” of the UK.

“Known throughout the world as the birthplace of the industrial revolution, Manchester has a proud history in science, politics, music, arts and sport. The city centre is jam-packed with unique and eclectic restaurants, bars, shops, museums, galleries, hotels and places to stay whilst the surrounding Greater Manchester boroughs offer a patch-work of visitor experiences including quaint market towns, traditional pubs and beautiful green spaces and waterways to be explored on foot or bike.” [visitmanchester.com]
**Delegate Details**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Forename:</th>
<th>Surname:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Company/Organisation:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postcode:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Telephone:</td>
<td>Direct Fax:</td>
<td></td>
</tr>
<tr>
<td>Mobile:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signature:</td>
<td>Date:</td>
<td></td>
</tr>
</tbody>
</table>

**Registration Fees**

<table>
<thead>
<tr>
<th>Event Type</th>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry Delegates (Biopharma, Pharma or Biotech Companies)</td>
<td>2-day pass (with complimentary access to the pre-event workshop)</td>
<td>£599 plus VAT</td>
</tr>
<tr>
<td></td>
<td>Day 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 2</td>
<td></td>
</tr>
<tr>
<td>Academic Delegates</td>
<td>2-day pass (with complimentary access to the pre-event workshop)</td>
<td>£320 plus VAT</td>
</tr>
<tr>
<td></td>
<td>Day 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 2</td>
<td></td>
</tr>
<tr>
<td>Vendor Delegates (CROs, Consultants, Technology and Service Providers)</td>
<td>Series Only</td>
<td>£1750 plus VAT</td>
</tr>
<tr>
<td></td>
<td>Poster Presentation</td>
<td>£250 plus VAT</td>
</tr>
</tbody>
</table>

**PROMOTIONAL LITERATURE DISTRIBUTION**

- Distribution of your company's promotional literature to all Series attendees: £999 plus VAT

**How to Pay**

<table>
<thead>
<tr>
<th>Payment Option</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Academic del(s)</strong></td>
<td>Special Offer: 3 for 2</td>
</tr>
<tr>
<td><strong>Vendor dels</strong></td>
<td>Offer is only valid on the Series and for those registering at Industry or Academic rates</td>
</tr>
</tbody>
</table>

**Please choose one of the following payment options:**

- **CREDIT CARD:**
  - An Oxford Global representative will contact you directly following return of contract/booking form to process card payment.
  - If payment will be made by a colleague within your company, please complete the following:
    - Card Payment Contact Name: |
    - Phone Number: |

- **INVOICE:**
  - Invoice Address (if different from above) |
  - Please note there is a £50 plus VAT handling charge for payment via invoice |

---

**Biomarkers Series UK**

18 - 20 February 2020, Manchester Central Convention Complex, Manchester, UK

www.oxfordglobal.co.uk/biomarkers-series-uk/

**HOW TO REGISTER:**

FAX your booking form to +44(0)1865 689120 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk

---

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk

---

Once I have completed and returned this form, I would like to: (Please tick as appropriate)

- Access to the online conference presentations: £499 plus VAT

---

**Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:**

**Delegate Booking Fee**

- The Delegate Booking Fee includes lunches and refreshments throughout the Series, presentations and panel sessions, scheduled one-to-one meetings, and networking/social events. Series and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser.

**Cancellation and Curtailment**

- If you are offered a free delegate pass and you are unable to attend the Series, you may nominate a substitute delegate. The substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid a non-attendance charge of £200 plus VAT being applied.

- If a Registered Delegate is unable to attend the Series, he/she may nominate a substitute of equal standing within their Company. A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid cancellation charges being applied. Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

**Data Protection**

- The data controller is the organiser (Oxford Global Marketing Ltd). Registration details will be retained and used in accordance with our privacy policy. Your information may be shared with selected partners and contractors, solely for the for the purposes of the event.

---

*Please note there is a £50 plus VAT handling charge for payment via invoice.*

---

**Terms & Conditions of Booking**

---

*If you attend an event then a sponsor or exhibitor may scan your badge. This is the equivalent to handing over your business card. Should you allow your badge to be scanned, you are agreeing to share your personal information with the named sponsor.*
**FORTHCOMING EVENTS**

### Biologics Series
- **UK**
  - 13th Annual Proteins & Antibodies Congress
    27 - 29 April 2020 | London, UK
  - 7th Annual Peptides & Oligonucleotides Congress
    27 - 29 April 2020 | London, UK
  - 2nd Annual Bispecifics in Discovery & Development Congress
    27 - 29 April 2020 | London, UK
- **US**
  - 5th Annual Biomarkers & Precision Medicine USA Congress
    15 - 16 October 2020 | San Diego, USA

### Immuno Series
- **UK**
  - 5th Annual Advances in Immuno-Oncology Congress
    21 - 22 May 2020 | London, UK
  - Autoimmunity & Immunology Congress
    21 - 22 May 2020 | London, UK
  - 3rd Annual Advances in Immuno-Oncology USA Congress
    15 - 16 October 2020 | San Diego, USA

### PharmaTec Series
- **UK**
  - 18th Annual Pharmaceutical IT & Data Congress
    24 - 25 September 2020 | London, UK
  - 4th Annual Artificial Intelligence in Drug Development Congress
    24 - 25 September 2020 | London, UK
  - 2nd Annual SmartLabs & Laboratory Informatics Congress
    24 - 25 September 2020 | London, UK

### Cell Series
- **UK**
  - 9th Annual Cell Culture & Bioprocessing Congress
    06 - 07 October 2020 | London, UK
  - 7th Annual Regenerative Medicine & Advanced Therapy Development Congress
    06 - 07 October 2020 | London, UK
  - 6th Annual Cell & Gene Therapy Manufacturing Congress
    06 - 07 October 2020 | London, UK
- **EU**
  - 21st Annual Drug Discovery Summit
    26 - 27 May 2020 | Berlin, Germany
  - 8th Annual Drug Design and Medicinal Chemistry Congress
    26 - 27 May 2020 | Berlin, Germany
  - 2nd Annual Neuroscience Drug Discovery Congress
    26 - 27 May 2020 | Berlin, Germany

### Formulation & Delivery Series
- **UK**
  - 6th Annual Formulation & Drug Delivery Congress
    22 - 23 April 2020 | London, UK
  - 5th Annual Inhalation & Respiratory Drug Delivery Congress
    22 - 23 April 2020 | London, UK
  - Biomanufacturing Congress
    22 - 23 April 2020 | London, UK
  - 3rd Annual Formulation & Drug Delivery USA Congress
    17 - 18 March 2020 | San Diego, USA
  - 3rd Annual Inhalation & Respiratory Drug Delivery USA Congress
    17 - 18 March 2020 | San Diego, USA

### Biomarkers Series
- **UK**
  - 15th Annual Biomarkers Congress
    18 - 20 February 2020 | Manchester, UK
  - Genomic Markers Congress
    18 - 20 February 2020 | Manchester, UK
- **US**
  - 5th Annual Biomarkers & Precision Medicine USA Congress
    15 - 16 October 2020 | San Diego, USA

### R&D Series
- **UK**
  - 12th Annual Next Generation Sequencing & Clinical Diagnostics Congress
    05 - 06 November 2020 | London, UK
  - 8th Annual Single Cell Analysis Congress
    05 - 06 November 2020 | London, UK
  - 6th Annual Genome Editing Congress
    05 - 06 November 2020 | London, UK
  - 2nd Annual Digital PCR Congress
    05 - 06 November 2020 | London, UK
  - 6th Annual Next Generation Sequencing USA Congress
    07 - 08 April 2020 | Boston, USA
  - 6th Annual Single Cell Analysis USA Congress
    07 - 08 April 2020 | Boston, USA
  - 4th Annual Genome Editing USA Congress
    07 - 08 April 2020 | Boston, USA

### NextGen Omics Series
- **UK**
  - 12th Annual Next Generation Sequencing & Clinical Diagnostics Congress
    05 - 06 November 2020 | London, UK
  - 8th Annual Single Cell Analysis Congress
    05 - 06 November 2020 | London, UK
  - 6th Annual Genome Editing Congress
    05 - 06 November 2020 | London, UK
  - 2nd Annual Digital PCR Congress
    05 - 06 November 2020 | London, UK
  - 6th Annual Next Generation Sequencing USA Congress
    07 - 08 April 2020 | Boston, USA
  - 6th Annual Single Cell Analysis USA Congress
    07 - 08 April 2020 | Boston, USA
  - 4th Annual Genome Editing USA Congress
    07 - 08 April 2020 | Boston, USA

### COMPLIMENTARY RESOURCES
Visit www.oxfordglobal.co.uk/hub/ to gain access to our complimentary resources, including Videos, Webinars Recordings, Q&As, Industry Reports, Newsletters, and much more!